Innovation

A blood-based diagnostic test for neurodegenerative diseases is a global priority By Zivjena Vucetic 03/21/2025 As the global population ages, the incidence of neurodegenerative diseases such as Alzheimer’s disease (AD) is rapidly increasing. By 2050, the global population of people over the age of 60 is expected to double, reaching 2.1 billion individuals, while those over 80 […]

By Allie Corey Published  March 11, 2025 6:01pm EDT FOX 13 News Ironman athlete with Alzheimer’s sets a new goal FOX 13’s Allie Corey highlights Scott Berkheiser, who is inspiring others by competing in the Ironman Triathlon despite being diagnosed with early-onset Alzheimer’s at 55 years old. The Brief TAMPA, Fla. – The Ironman Triathlon is a grueling […]

By Katie Taranto; Published March 10, 2025 at 3:45PM A Dominion Hills woman diagnosed with early-onset Parkinson’s disease received national recognition last month for her advocacy work. Allison Signorelli was honored with the Citizen Scientist Cultivator Award for participating in various research trials after being diagnosed with the disease in 2022 at age 47. Signorelli has spent the […]

 International non-profit expands research network to Syracuse to improvecommunity access to research opportunities Washington D.C., Mar. 10, 2025- Global Alzheimer’s Platform Foundation® (GAP) announces the addition of Ichor Research, a leading private a clinical research organization based in Syracuse, New York, to its global network of over 100 best-in-class research sites. Specializing in neurodegenerative clinical trials, […]

GAP Citizen Scientist awards honor individuals’ contributions to research by Andrea Lobo | March 6, 202 A research advocate diagnosed with Parkinson’s disease and a former nurse with Alzheimer’s disease were among recipients of volunteer awards from the Global Alzheimer’s Platform Foundation (GAP).AGAP’s Citizen Scientist Awards acknowledge the contributions of volunteers in clinical trials for neurodegenerative diseases. Each year, GAP’s network of research sites, […]

The free clinical trial at Axiom Brain Health in Tampa works to detect early signs of Alzheimer’s and other cognitive diseases, even years before symptoms appear. Author: Hannah Dineen Published: 4:04 PM EST March 6, 2025 Updated: 8:52 PM EST March 6, 2025 TAMPA, Fla. — It’s estimated nearly 7 million people in the U.S. are living with Alzheimer’s disease. […]

Washington D.C., Feb. 28, 2025 -The Global Alzheimer’s Platform Foundation® (GAP) proudly announced the 2024 National Citizen Scientist Awards® elevated honorees at their 2025 GAP-Net Site Optimization Conference in Miami, Florida. GAP’s Citizen Scientist Awards (CSA) celebrate the contributions of individuals who make a difference by volunteering in clinical trials for neurodegenerative diseases. This year’s […]

Ralph Kern, MD, MHSc, CMO of Cognito Therapeutics, discusses scaling up clinical trials, integrating patient centricity and transitioning from therapeutics to device treatments. February 13, 2025 Tell us about the scientific foundation behind the Spectris ADTM device. Our non-invasive investigational Spectris ADTM device evokes 40 Hz brain gamma oscillations through audiovisual stimulation. It’s delivered in […]

Could a headset with flashing lights and sounds stimulate brain waves and treat Alzheimer’s? Cognito’s Phase 3 trial on such a device is trying to answer that question. Neuropsychologist Dr. Michelle Papka, the trial’s principal investigator and founder of the CRCNJ, explains the science. Researchers and technology companies are investigating whether non-invasive electromagnetic, visual, and […]

The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum of understanding, the consortium, led by scholars from Harvard University, will gain early access to Bio-Hermes-001 data to investigate the potential for […]

Collaboration to accelerate the investigation of Alzheimer’s disease biomarkers with early access to Bio-Hermes-001 data  Washington D.C., Jan. 30, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to announce a collaboration with the Biomarkers of Aging Consortium, a consortium dedicated to the developing and validating biomarkers for aging and longevity. Through a memorandum […]

Washington D.C., Jan. 23, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Beckman Coulter Diagnostics as a strategic partner in the Bio-Hermes-002 study. This first-time collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images […]

By Austin Montgomery| December 11, 2024 Global Alzheimer’s Platform Foundation (GAP) has partnered with Eli Lilly and Company (NYSE: LLY) for a study comparing blood tests that could help predict and diagnose Alzheimer’s disease. The Bio-Hermes-002 study looks to increase participation of underrepresented older adults within typical Alzheimer’s clinical research, with at least 25% participation earmarked […]

Some turn to clinical trials to access breakthrough drugs By Cindy Krischer Goodman | cgoodman@sunsentinel.com | South Florida Sun Sentinel UPDATED: December 11, 2024 at 8:00 AM EST The federal Food & Drug Administration has approved two new Alzheimer’s medications that can offer people more time to live normally, but accessing them in Florida is complicated. Hold-ups related to insurance […]

The Global Alzheimer’s Platform Foundation (GAP) is excited to announce its collaboration with Eli Lilly and Company on the transformative Bio-Hermes-002 study. This partnership is poised to broaden the understanding of Alzheimer’s disease by integrating advanced biomarkers that may assist in its early detection and diagnosis. Significance of the Bio-Hermes-002 Study Like its predecessor, Bio-Hermes-001, […]

Citizen Scientists Suzanne and Mike O’Brien of #GAPNet site JEM Research Institute

ViewMind Precision Neurological Assessments ViewMind Digital BiomarkerPublished 7:31 AM EST, December 10, 2024Share To Enhance Alzheimer’s Diagnosis Through Diverse Biomarker Analysis “We expect ViewMind’s promising technology to offer the field alternative methods for detecting and diagnosing Alzheimer’s disease.”— John Dwyer, President of the Global Alzheimer’s Platform Foundation NEW YORK CITY, NY, UNITED STATES, December 10, […]

Washington D.C., Dec. 9, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Eli Lilly and Company (Lilly) to the Bio-Hermes-002 study. This collaboration will enrich the unique, observational platform study that compares blood-based and digital biomarkers across a broad range of races and ethnicities that may help predict and diagnose Alzheimer’s […]

By ActionNewsJax.com News Staff, November 18, 2024 at 5:32 pm EST Jacksonville Center for Clinical Research just joined the Global Alzheimer’s Platform Foundation’s national network of research centers. According to a news release, the JCCR has conducted more than 1,000 clinical trials over 25 years. Global Alzheimer’s Platform President John Dwyer said the organization wants to […]

Washington D.C., Nov. 18, 2024- Global Alzheimer’s Platform Foundation® (GAP) is welcoming a new clinical research site into its international network of best-in-class research sites, Jacksonville Center for Clinical Research of Jacksonville, Florida. Jacksonville Center for Clinical Research (JCCR) is a premier clinical research site, having conducted more than 1,000 clinical trials over 25 years with […]

Contify Life Science News Nov 3 • 11:52 PM *Cognivue’s participation in the study will help predict underlying AD pathologies and analyze MRI, neuroinflammation, and longitudinal data. Oct. 30– Cognivue issued the following news release:. Its proven ability to distinguish between cognitively normal individuals, those with MCI, and mild dementia— regardless of amyloid status., Validated […]

By Robbie Owens, November 1, 2024 / 6:05 PM CDT / CBS Texas DALLAS – If you dare, just look at the numbers associated with Alzheimer’s: nearly 7 million Americans are diagnosed with the disease right now. According to the Alzheimer’s Association, the potential lifetime impact is 1 in 3. Gail Youngdale is one of them. “My mother […]

Oct 30, 2024 | staff reporterSave for later NEW YORK – The Global Alzheimer’s Platform (GAP) Foundation has launched the Bio-Hermes-002 study, in which it will continue to explore biomarkers that can predict the likelihood that a patient has amyloid and tau accumulations in their brains, signaling a potential Alzheimer’s diagnosis. The Alzheimer’s research-focused nonprofit announced the […]

Global Alzheimer’s Platform Foundation Announces Strategic Partnerships for the Transformative Bio-Hermes-002 Study   Washington D.C., Oct. 28, 2024 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome the initial strategic partners in the Bio-Hermes-002 study. These collaborations will enhance the unique, observational platform study that compares blood-based and digital biomarkers across a broad range […]